Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Abacavir/Lamivudine/Dolutegravir in HIV-1
NCT02067767Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by CHU de Nantes. Started Feb 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02067767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067767.